ATAI Life Sciences NV
NASDAQ:ATAI
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ATAI Life Sciences NV
Cash Equivalents
ATAI Life Sciences NV
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Cash Equivalents
$85.3m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Cash Equivalents
€6.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
10%
|
CAGR 10-Years
14%
|
|
|
Merck KGaA
XETRA:MRK
|
Cash Equivalents
€2.7B
|
CAGR 3-Years
14%
|
CAGR 5-Years
15%
|
CAGR 10-Years
13%
|
|
|
MPH Health Care AG
XETRA:93M1
|
Cash Equivalents
€1m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Cash Equivalents
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ATAI Life Sciences NV
Glance View
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company engages in the treatment of mental health disorders. The company is headquartered in Berlin, Berlin and currently employs 81 full-time employees. The company went IPO on 2021-06-18. The firm is aiming to transform the treatment of mental health disorders.
See Also
What is ATAI Life Sciences NV's Cash Equivalents?
Cash Equivalents
85.3m
USD
Based on the financial report for Dec 31, 2025, ATAI Life Sciences NV's Cash Equivalents amounts to 85.3m USD.
What is ATAI Life Sciences NV's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
-3%
Over the last year, the Cash Equivalents growth was 387%. The average annual Cash Equivalents growth rates for ATAI Life Sciences NV have been -24% over the past three years , -3% over the past five years .
